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getting a positive final test result (i.e. wrongly continued). The developed software 
(i.e. R-codes) can easily be applied to other cases.
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Negative ReiMbuRseMeNt CoNsequeNCes FRoM tRial DesigN ChoiCes
Jaksa A., Westbrook L., Daniel K., Ho Y.S.
Context Matters, Inc., New York, NY, USA
Objectives: Health Technology Assessments (HTA) use clinical trial data to deter-
mine comparative efficacy and cost-effectiveness; thus study design plays a roll 
in market access. The objective is to determine how often reimbursement deci-
sions cite trial design defects. MethOds: We analyzed 1,702 HTAs from CADTH, 
G-BA, HAS, NICE, PBAC, and SMC. We examined the clinical assessment rationale 
for the decision and the reimbursement decisions. An explicit trial design defect 
was defined as a clinical assessment of “inappropriate comparator” or “inappro-
priate patient population.” Clinical assessments of lower, uncertain, or unknown 
efficacy or a clinical determination of insufficient or lack of evidence were defined 
as potential trial design defects. Results: Reviews that cited trial defects resulted 
in significantly more negative reimbursement decisions (6.6%) than positive reim-
bursement decisions (0.4%; p< .001). This pattern held true for each individual 
agency examined. G-BA was the agency most likely to cite an explicit trial deficit 
(39%), while HAS was the least likely (0.6%). In addition, significantly more reviews 
that cited a potential trial defect resulted in negative reimbursement decisions (44%) 
than positive reimbursement decisions (5.5%; p< .001). This also held true for each 
agency. Again, G-BA was most likely to note a potential trial defect in reviews (46%) 
while SMC was least likely (6.4%). Among disease conditions with more than 10 
reviews, explicitly cited trial defects were mostly frequently seen in Cystic Fibrosis 
and Parkinson’s Disease (15% and 13%, respectively). Potential trial defects were 
most frequently cited in Atrial Fibrillation and Depression reviews (42% and 39% 
respectively). cOnclusiOns: Explicit and potential trial design issues have nega-
tive consequences for reimbursement outcomes. Negative decisions are more likely 
than positive decisions to cite trial design issues. G-BA is more inclined than other 
agencies to cite these trial design issues when issuing their reimbursement deci-
sions. Manufacturers should consider market-access outcomes when designing 
clinical trials.
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eviDeNCe ResultiNg FRoM ChaRt Review MethoDology aPPlieD 
to NaMeD PatieNt PRogRaMMe PaRtiCiPatioN aND CoMPassioNate 
MeDiCatioN use: PeRi-aPPRoval aPPRoxiMatioN oF Post-MaRket 
PRaCtiCe PatteRNs aND Costs
Stein D.1, Jean-Mary J.2, Goldwin A.E.2, Lau M.R.3, Manson S.3
1UBC: An Express Scripts Company, Dorval, QC, Canada, 2United BioSource Corporation, London, 
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Objectives: Compassionate use programmes provide peri-approval drug access 
based on unsolicited physician requests for patients with unmet need. Practice 
pattern evaluations in this context, using chart review methodology, permits the 
collection of pre-approval data outside of clinical trial settings that can approxi-
mate real-world post-market use. Data can be used to inform important economic 
evaluations, value dossiers, and drug safety assessments. MethOds: Study design 
and operational considerations related to chart review studies of compassionate 
use populations have been summarized by evaluating three multi-national case 
studies. Results: The source populations of patients were drawn from compas-
sionate use programmes providing oral anti-cancer therapies. These were initi-
ated pre-approval following positive clinical trial findings. Countries included 
Australia, Belgium, Greece, Ireland, Israel, Italy, The Netherlands, New Zealand, 
Spain, Switzerland and the United Kingdom. Data including patient character-
istics, patterns of care and drug dosing, duration of treatment and reasons for 
treatment discontinuation, overall survival, clinical benefit, progression free sur-
vival and adverse and serious adverse events are being collected to inform health 
economic and other burden of illness assessments. Site and patient selection was 
performed using compassionate use enrollment data, facilitating an efficient study 
start-up. Data were cleaned at point of data entry and via an electronic query pro-
cess in real-time resulting in tailored international datasets. Patients provided con-
sent for their medical data to be used prior to initiating compassionate use therapy, 
and additional ethical approval for the chart review was sought on a local and/
or national level. Chart review study design requires a balance between scientific 
and operational rigor and practicality and feasibility. cOnclusiOns: Peri-approval 
chart review studies of patients in compassionate use programmes offer an impor-
tant opportunity to characterize patterns of use and associated treatment costs as 
well as the clinical impact of investigational medications in non-trial settings to 
inform clinical, health economic and market access decisions.
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iMMatuRe suRvival Data FRoM eaRly tRial teRMiNatioN – theoRy aND 
hta PRaCtiCe
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Objectives: Scientific research suggests that randomized controlled trials ter-
minated early for benefit considerations systematically overestimate treatment 
effects of the primary outcome. This study assessed whether Health Technology 
Assessment (HTA) agencies accept the increased uncertainty around overall survival 
(OS) estimates in oncology trials arising from early termination. MethOds: Public 
scientific databases were searched to identify scientific articles and pivotal trials 
involving early trial termination. A selection of related HTA appraisals, published 
between January 2011 and February 2014, were analysed. Current scientific evidence 
on the impact of early stopping on outcome estimates was compared to the conclu-
sions made by 11 HTA agencies. Results: Twelve scientific articles, 12 pivotal trials, 
and 31 related HTA appraisals were selected for in-depth analysis. The scientific 
literature suggests that more stringent significance levels in the repeated interim 
the algorithms’ PPV. cOnclusiOns: We have demonstrated that MC/PV algorithms 
can be used to identify PsO patients with a high degree of accuracy, while PsO-AC 
accuracy requires further investigation. Such methods allow researchers to conduct 
retrospective studies in databases where diagnosis codes are absent.
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assessiNg the eFFeCtiveNess oF CouNteR MatChiNg FoR iMPRoviNg 
the eFFiCieNCy oF the NesteD Case-CoNtRol DesigN iN obseRvatioNal 
stuDies
Kiri V.1, MacKenzie G.2
1FV & JK Consulting Ltd, Guildford, UK, 2University of Limerick, Limerick, Ireland
Objectives: The nested case-control (NCC) design offers a simple method for 
avoiding unreasonable assumptions in the evaluation of time-dependent treat-
ment effect. Its results are easy to interpret. Its strength rests largely on the appro-
priateness of the controls which are matched to the cases- suggesting a matching 
strategy that ensures maximum number of discordant case-control pairs may be 
more efficient since effect estimation is based entirely on the off-diagonal data of 
the resulting 2x2 tables in the conditional logistic regression. In theory, the more 
off-diagonal pairs that are generated by the random sampling scheme, the more 
improvement we can expect on efficiency. The objective of this study is to assess the 
efficiency of counter-matching on treatment compared with the classical matching 
approach in the NCC design based on results from the cohort design using simulated 
data. MethOds: In each simulation of 1000 patients at 100 replications per run, we 
assumed an underlying event hazard of Weibull distribution using inputted values 
for the scale and shape parameters, treatment, age and sex as the factors. Each 
run involved distinct treatment prevalence of between 10%-50% with event rate 
varying from common to very rare. We compared the proportion of matched pairs 
(at 1 control per case) used in the analyses of the resulting data between the classi-
cal and counter matching strategies. Results: The counter-matched strategy was 
more efficient than the classical approach. The proportion of matched pairs used 
was on average over ten times more and it also gave mean effect estimates which 
were more consistent with the full cohort values, particularly for low treatment 
exposure and rare events. cOnclusiOns: Our results suggest counter matching is 
more efficient and more accurate estimates than classical matching in nested case-
control design. These benefits may be particularly important for studies involving 
rare events or low treatment exposure.
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Objectives: To assess the methodological quality of randomized controlled trials 
(RCTs) published in “Russian Allergology Journal” (RAJ) in 2009-2013. MethOds: 
Retrospective analysis of 96 original publications was carried out. For 8 RCT the 
risks of biases were assessed using the methodology of the Cochrane Collaboration. 
Accuracy of statistical analysis was assessed in accordance with established in 
2009 journal’s requirements, made in accordance with best international prac-
tice. Results: 96 articles were analysed, 8 (8%) of them were identified as RCTs. All 
the RCTs have a high risk of the biases and major mistakes in the statistical analy-
sis. cOnclusiOns: The methodological quality of RCTs is insufficient and needs 
to be improved. We consider that the most important role should play improvement 
of trials’ planning. Collaboration with the experts in clinical trials’ methodology 
is strongly recommended. The analysis empowers researchers to consider exist-
ing experience and to improve methodological quality of RCTs, their relevance to 
international standards.
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siMulatioN oF aN aDDitioNal go/No-go eFFiCaCy iNteRiM aNalysis iN a 
heaD-to-heaD RCt
Van Montfort K.
Nyenrode Business University, Breukelen, The Netherlands
Objectives: A head-to-head randomized clinical trial (RCT) to evaluate a new 
drug is financially risky, because a positive outcome is uncertain. We simulate 
and evaluate a head-to-head RCT design incorporating an additional go/no-go 
efficacy interim analysis to show the consequences of this additional interim anal-
ysis. MethOds: We simulate the endpoint event-free-survival (EFS) of patients 
in a head-to-head RCT. The decision rule of the additional interim efficacy analy-
sis (i.e. stop or continue) depends on the number of patients (i.e. 300,400 or 500 
patients) and the significance level (i.e. α = 0.05, α = 0.10 or α = 0.20) of the interim 
analysis. The RCT without an interim-analysis has significance level α = 0.05, 
power= 0.86 and sample size 800. Results: Each combination of sample size 
and significance level, which is called a scenario, is investigated by simulating 
2,000 trials of 800 patients. Per simulated scenario we report, among others, the 
“Probability of positive final analysis test result GIVEN negative interim analysis 
test result” (= wrongly stopped) and the “Probability of negative final analysis 
test result GIVEN positive interim analysis test result” (= wrongly continued). 
The results of the first scenario, i.e. an interim analysis at 300 included patients 
and significance level α = 0.05, are as follows. If the actual improvement of the EFS 
hazard rate is 0%, the abovementioned probabilities are 3.65% and 7.85%. An actual 
improvement effect of 5% changes the probability values to 20.25% and 12.80, 
while an actual improvement effect of 10% causes the probability values 28.50% 
and 5.55%. cOnclusiOns: The simulated probabilities were mainly influenced 
by the actual EFS improvement. The smaller the actual outcome improvement, the 
greater the probability of continuing the trial up to 800 included patients without 
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The mapping of paediatric vaccination process in the United Kingdom (UK), as a 
precursor of a real-world study, is described. MethOds: A targeted review of pub-
licly available information was conducted to gain comprehensive understanding 
of the paediatric vaccination process in the UK. A survey was designed eliciting 
the chronology of vaccination process prior to and on vaccination day, including 
estimates of active health care professional involvement. Face-to-face interviews 
with a nurse were conducted at three general practitioner surgeries routinely 
performing vaccinations. A subsequent follow-up call with each nurse was also 
arranged. Descriptive statistics were generated and preliminary cost calculations 
made. Results: Paediatric vaccination process can be broken down in 6 and 8 
clearly discernible steps prior to and on vaccination day, respectively. Activities 
prior to vaccination day include, among others, inventory, ordering, cold-chain 
management and are typically for multiple subjects. Mean time for those activities, 
recalculated per single vaccination visit, was 6.7 minutes, of which 61% dedicated 
to administrative duties. Activities on vaccination day include, among others, room 
preparation, consultation, vaccine administration. Estimated time per single visit 
totaled 25.4 minutes. Estimated total cost per single vaccine administration, with 
nurse salary cost from PSSRU, was £10.4. Costs may vary substantially depending 
on the level of “on-costs” to nurse’s gross salary. cOnclusiOns: The detailed 
mapping of paediatric vaccination process in the UK identified clearly discernible 
tasks, time estimates, factors impacting variability of time outcomes, and early 
cost estimates. This forms the basis of a real-world T&M study aiming to generate 
robust time and cost outcomes.
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CoMPaRative eFFeCtiveNess ReseaRCh oF MeDiCal DeviCes – New 
MethoDs NeeDeD?
Hunger T.1, Schnell-Inderst P.2, Arvandi M.1, Conrads-Frank A.1, Siebert U.1
1UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria, 
2UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. T.; Innsbruck, 
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Objectives: Guidelines for Health Technology Assessment (HTA) and Comparative 
Effectiveness Research (CER) largely focus on pharmaceuticals and only few explic-
itly consider other health care technologies. CER of medical devices (MD) faces some 
challenges that raise questions about how adequate current CER methods account 
for the specific features of MD and how well MD fit in the paradigm of drug HTA. Our 
aim was to identify challenges and gaps in methodology related to specific issues 
of MD. Our comprehensive framework for the evaluation of clinical effectiveness of 
MD includes recommendations for generation of primary data and analyzing and 
synthesizing data in systematic reviews of CER of MD. MethOds: We performed a 
targeted literature review for CER methods and specific features of MD. An electronic 
database search was combined with systematic screening of tables of content of 
selected journals in the fields of epidemiology, HTA, statistics, and evidence-based 
medicine, which have a strong focus on methods. Additionally, we screened the 
reference lists of the most relevant papers. Results: More than 200 publications 
about the general evaluation of MD and about specific CER methods were included. 
The MD’s physical mechanism of action, the dynamic development and regulatory 
evidence requirements are the driving features that suggest the increased use of 
certain methods for the evidence generation, finding of information for HTA, data 
analysis and synthesis, and interpretation of results. Rather than following the para-
digms of drug evaluation, MD resemble more the notion of complex interventions. 
Our methodological framework is compatible with the EUnetHTA core model and 
integrates existing recommendations for other complex interventions. The con-
sideration of observational data, operator characteristics, active control trials, and 
decision-analytic modeling are of special importance, as well as the application of 
Bayesian methods. cOnclusiOns: The assessment of the clinical effectiveness of 
MD does require specific, although not necessarily new methods.
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(Cost-) eFFeCtiveNess oF a Multi-CoMPoNeNt iNteRveNtioN FoR aDults 
with ePilePsy: stuDy PRotoCol oF a DutCh RaNDoMizeD CoNtRolleD 
tRial
Wijnen B.1, Leenen L.A.M.2, de Kinderen R.J.A.1, Majoie M.H.2, van Heugten C.M.3, Evers S.M.1
1Maastricht University, Maastricht, The Netherlands, 2Epilepsy Center Kempenhaeghe, Heeze, The 
Netherlands, 3MHENS, School for Mental Health and Neuroscience, Maastricht, The Netherlands
Objectives: Poor adherence to anti-epileptic drugs has been shown to be the 
most important cause of poorly controlled epilepsy. Furthermore, it is emphasized 
that an increase in quality of life among patients with epilepsy could be reached 
by counseling and treatments aimed at increasing their self-efficacy and thus 
stimulate self-management. However, there is a need for evidence on the effec-
tiveness of such programs, especially within epilepsy care. Therefore, we have 
developed a multi-component intervention (MCI) which combines a self-manage-
ment/education program with e-Health interventions. Hence the overall objec-
tive of this study is to assess the (cost-) effectiveness of a MCI aiming to improve 
self-efficacy in people with epilepsy compared to care as usual. MethOds: A 
randomized controlled trial in 2 parallel groups will be conducted to compare 
the MCI intervention with a waiting list control condition in epilepsy patients. 
One hundred eligible epilepsy patients will be recruited from the Kempenhaeghe 
epilepsy center and allocated to intervention or control group. Patients in the 
intervention group will receive an education program of six meetings including 
e-Health intervention and will be followed for 12 months. Patients in the control 
group will be followed for 6 months after which they will be offered to participate 
in the MCI. The study will consist of three parts: 1) a clinical effectiveness study, 
2) a cost-effectiveness study, and 3) a process evaluation. The primary outcome 
will be self-efficacy. Outcome assessments will be done using questionnaires at 
baseline and after 3, 6, 9, and 12 months. Results: N/A. cOnclusiOns: This 
study will determine the (cost-) effectiveness of an MCI intervention to improve 
the self-efficacy of epilepsy in adult patients. The MCI is designed to stimulate 
self-management skills and awareness of epilepsy patients in combination with 
analyses reduce the probability of finding significant results due to chance while 
large numbers of outcome events reduce the overestimation of treatment effects. 
Our analysis finds that a statistically significant gain in OS is an important deci-
sion driver for even the most critical HTA agencies, although the treatment effect 
may still be questioned when the trial is unblinded early. HTA agencies appreciate 
to receive the latest available information (UK, Australia and Germany) and may 
reject the use of oncology drugs when there is too much uncertainty around OS 
estimates to justify the proposed price. It is generally useful to continue data col-
lection and follow-up patients should HTA agencies still request more reliable OS 
estimates for modeling purposes (UK and Australia) or long-term risk-benefit evalu-
ation (France). cOnclusiOns: Payers are aware of the overestimation of effect size 
due to early trial termination and may reject drugs for high uncertainty around OS 
estimates. For adequate responses to requests for more reliable data, it is advised 
to continue data collection and follow-up patients.
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the MaNageMeNt oF iRRitable bowel syNDRoMe (ibs) iN eNglaND: a 
Real woRlD stuDy iN PRiMaRy CaRe CliNiCal PRaCtiCe
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Objectives: IBS is often a diagnosis of exclusion, with poor diagnosis coding in 
primary care and identification of eligible research participants challenging. We 
present the methodology of an on-going multi-centre, observational, retrospec-
tive research study, designed to overcome the challenges of IBS patient identifica-
tion. MethOds: FARSITE, a software tool for identification of research participants 
developed by the Greater Manchester Comprehensive Local Research Network and 
North West eHealth, was used to screen anonymised primary care records for 
potentially eligible patients. Ethical approval reference 13/LO/0692. Search criteria: 
patients aged 18-60; combination READ code symptoms indicative of IBS and pre-
scription of IBS medications 01/01/2009–31/12/2011. GPs at 8 participating practices 
in Salford & Greater Manchester reviewed clinical records of the FARSITE-generated 
list of patients to apply full eligibility criteria for final patient selection. Inclusion 
criteria: medical diagnosis of IBS or meeting ROME III criteria; provision of consent. 
Exclusion Criteria: diagnosis excluding IBS; IBS symptoms secondary to other con-
dition; IBS medications only for non-GI symptoms. Results: FARSITE identified 
1089 (1.3%) patients, of which 297 (27.3%) were eligible. 97 patients consented to 
participation (79% female). Main reasons for non-eligibility were not meeting ROME 
III criteria or IBS excluded by medical opinion. Patients were most commonly coded 
as irritable colon (37%), difficulty defecating (21%), abdominal pain (18%), diarrhoea 
symptoms (14%). Four (4%) patients had a READ code specific for IBS. The median 
(IQR) time from 1st presentation with abdominal symptoms to study eligibility was 
3.98 (0.00-9.04) years. cOnclusiOns: Identification of patients with IBS using READ 
codes is sub-optimal in primary care. A combination search of READ codes with 
symptom and prescription data via FARSITE has enabled potential participants to 
be identified with a reasonable screening failure rate. FARSITE is a valuable research 
tool aiding study feasibility by reducing the need for manual patient identification.
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the eFFeCt oF a likely oveReMPhasis oN FiCieNCy-RelateD test 
attRibutes oN aCMg ReCoMMeNDatioNs aND aCCess to NewboRN 
sCReeNiNg (Nbs)
Rittenhouse B.
MCPHS University, Boston, MA, USA
Objectives: Patient access to NBS has been greatly influenced by the 2006 
American College of Medical Genetics (ACMG) recommended expansion of NBS. 
ACMG relied largely on a stakeholder survey on 19 attributes of 84 rare conditions. 
The percentage of respondents agreeing to an attribute’s presence for a condition, 
along with its weight, determined attribute score. Sums of scores determined the 
entry point to an algorithm for final recommendations. This research examines 6 
attributes that appear to be associated with the same concept and asks whether 
these are really one (over-weighted) concept. MethOds: The ACMG report pro-
vided attribute scores. Six questions addressed test efficiency (simplicity, high 
throughput, cost < $1/condition, multiple analytes/test run, other conditions 
identified/analyte, multiple conditions detected/test). We examined correlations 
between the 6 answers for a given condition across conditions and associations 
with recommendations. Results: After eliminating conditions with missing data, 
78 remained. Pairwise correlations between the 6 answers were high (mean= .85; 
range, .72-.96). Of those conditions (37) scoring at least 75% of the possible points 
on one question (“high throughput”), 79% were recommended as Core conditions 
to be screened and only 8% were Not Recommended. The mean total scores for the 
6 similar questions was 339 (500 possible). Of those (19) scoring 25% or fewer of the 
possible points for that one question, only 3% were Core, 72% Not Recommended 
(mean score:89). cOnclusiOns: The high correlations support the idea that the 
6 similar questions were answered as if they were the same concept, weighting the 
common general attribute very highly. A more systematic approach, say MCDA, 
would likely have eliminated some of these questions with significant consequences 
for ACMG recommendations.
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woRkFlow MaPPiNg FoR PaeDiatRiC vaCCiNatioN PRoCess iN the uNiteD 
kiNgDoM (uk): a PReCuRsoR oF a tiMe aND MotioN (t&M) stuDy
Mokiou S.1, De Cock E.2, Standaert B.3
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Objectives: Time and Motion (T&M) methodology allows quantifying time-
related outcomes for a health care delivery process by disaggregating the process 
in its constituent parts to measure task durations. The design of a T&M study 
requires early process mapping to define the time outcomes to be measured. 
